1st Circ. Questions BioChemics Strategy In SEC Probe Case
The First Circuit prodded BioChemics Inc. on what it felt was an inconsistent argument Wednesday as the pharmaceutical company tried to flip a district court order denying coverage by Axis Reinsurance...To view the full article, register now.
Already a subscriber? Click here to view full article